Table II.
Comparison of patient characteristics in the PR/SD and PD groups.
| Variables | PR/SD (n=8) number (%) | PD (n=47) number (%) | P-value |
|---|---|---|---|
| Age (year) | 64.5±4.8 | 62.4±11.3 | 0.60 |
| Sex | |||
| Male | 5 (62.5) | 26 (55.3) | 0.71 |
| Female | 3 (37.5) | 21 (44.7) | |
| Location | |||
| Colon | 3 (37.5) | 31 (66.0) | 0.13 |
| Rectum | 5 (62.5) | 16 (34.0) | |
| Metastatic sites | |||
| 1 | 4 (50.0) | 17 (36.2) | 0.46 |
| >1 | 4 (50.0) | 30 (63.8) | |
| KRAS | |||
| Mutation | 2 (25.0) | 26 (55.3) | 0.08 |
| Wild-type | 6 (75.0) | 21 (46.7) | |
| Performance status (ECOG) | |||
| 0 | 1 (12.5) | 5 (10.6) | 0.10 |
| 1 | 5 (62.5) | 40 (85.1) | |
| 2 | 2 (25.0) | 2 (4.3) | |
| Serum CA19-9a | |||
| ≤37.0 u/ml | 5 (62.5) | 21 (44.7) | 0.35 |
| >37.0 u/ml | 3 (37.5) | 26 (55.3) | |
| Serum CEAa | |||
| ≤5.0 ng/ml | 4 (50.0) | 16 (34.0) | 0.39 |
| >5.0 ng/ml | 4 (50.0) | 31 (66.0) |
a
Serum CA19-9 and CEA levels were measured before chemotherapy. PD, progressive disease; SD, stable disease; PR, partial response; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen.